Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMX-C001 with factor Xa DOACs and unfractionated heparin in healthy subjects
NL-OMON53545Not yet recruiting
- Sponsor
- VarmX
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of VMX-C001 in Disease requiring anticoagulation (3 arms), sponsored by VarmX. Primary endpoint: Pharmacodynamic effect on unfractionated heparin anticoagulation. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
VMX-C001
03
Conditions
Disease requiring anticoagulation
Beyond the preview
Go deeper on NL-OMON53545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53545.